Design of Alternative Live Attenuated Influenza Virus Vaccines

2014 ◽  
pp. 205-235 ◽  
Author(s):  
Courtney Finch ◽  
Weizhong Li ◽  
Daniel R. Perez
Keyword(s):  
Influenza Virus ◽  
Live Attenuated Influenza Virus

scholarly journals Efficacy in Pigs of Inactivated and Live Attenuated Influenza Virus Vaccines against Infection and Transmission of an Emerging H3N2 Similar to the 2011-2012 H3N2v

2013 ◽  
Vol 87 (17) ◽  
pp. 9895-9903 ◽  
Author(s):  
C. L. Loving ◽  
K. M. Lager ◽  
A. L. Vincent ◽  
S. L. Brockmeier ◽  
P. C. Gauger ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Live Attenuated Influenza Virus

scholarly journals Functional immune response to influenza H1N1 in children and adults after live attenuated influenza virus vaccination

2019 ◽  
Vol 90 (4) ◽  
Author(s):  
Shahinul Islam ◽  
Fan Zhou ◽  
Sarah Lartey ◽  
Kristin G. I. Mohn ◽  
Florian Krammer ◽  
...  
Keyword(s):  
Immune Response ◽  
Influenza Virus ◽  
Virus Vaccination ◽  
Live Attenuated Influenza Virus ◽  
Influenza H1n1

scholarly journals Boosted Influenza-Specific T Cell Responses after H5N1 Pandemic Live Attenuated Influenza Virus Vaccination

2015 ◽  
Vol 6 ◽  
Author(s):  
YanChun Peng ◽  
Beibei Wang ◽  
Kawsar Talaat ◽  
Ruth Karron ◽  
Timothy J. Powell ◽  
...  
Keyword(s):  
Influenza Virus ◽  
T Cell ◽  
T Cell Responses ◽  
Virus Vaccination ◽  
Cell Responses ◽  
Live Attenuated Influenza Virus

scholarly journals Development of a Mouse-Adapted Live Attenuated Influenza Virus That PermitsIn VivoAnalysis of Enhancements to the Safety of Live Attenuated Influenza Virus Vaccine

2014 ◽  
Vol 89 (6) ◽  
pp. 3421-3426 ◽  
Author(s):  
Andrew Cox ◽  
Steven F. Baker ◽  
Aitor Nogales ◽  
Luis Martínez-Sobrido ◽  
Stephen Dewhurst
Keyword(s):  
Influenza Virus ◽  
Virus Vaccine ◽  
Safety Analysis ◽  
Influenza Virus Vaccine ◽  
Safety Concerns ◽  
High Doses ◽  
Live Attenuated Influenza Virus

The live attenuated influenza virus vaccine (LAIV) is preferentially recommended for use in persons 2 through 49 years of age but has not been approved for children under 2 or asthmatics due to safety concerns. Therefore, increasing safety is desirable. Here we describe a murine LAIV with reduced pathogenicity that retains lethality at high doses and further demonstrate that we can enhance safetyin vivothrough mutations within NS1. This model may permit preliminary safety analysis of improved LAIVs.

scholarly journals The Usage of Influenza Vaccine to Prevent Seasonal Influenza during Pandemic COVID-19

2021 ◽  
Vol 8 (2) ◽  
pp. 93
Author(s):  
Yelvi Levani ◽  
Ayu Lidya Paramita
Keyword(s):  
Influenza Virus ◽  
Influenza Vaccine ◽  
Elderly People ◽  
Seasonal Influenza ◽  
Morbidity And Mortality ◽  
Acute Respiratory Disease ◽  
Seasonal Flu ◽  
Airborne Disease ◽  
Live Attenuated Influenza Virus ◽  
Virus Influenza

Influenza is an acute respiratory disease caused by influenza virus. Influenza can affect million people in every year and causing morbidity. Some of cases can be severe and need hospitalized, especially in elderly people. Influenza is an airborne disease and can spread rapidly. Every seasonal flu can be different because Influenza virus do mutation. Influenza vaccine can reduce morbidity and mortality. There are two types of influenza vaccine; live attenuated influenza virus (LAIV) and inactivated influenza virus (IIV). The newest type of influenza vaccine consists four types of virus (quadrivalent), therefore it gives more protection compared to the older one. Influeza vaccine is still recommended during pandemic COVID-19 because it can prevent co-infection between Influenza and COVID-19. In addition, it can reduce the morbidity and mortality during pandemic COVID-19.

Sign in / Sign up

Export Citation Format

Share Document